Evidence map›Paper›PMID 28824460›Full record

ArticleFrontiers in physiology2017

Anti-inflammatory Effects of Fungal Metabolites in Mouse Intestine as Revealed by

Dominik Schreiber, Lisa Marx, Silke Felix, Jasmin Clasohm, Maximilian Weyland, Maximilian Schäfer, Markus Klotz, Rainer Lilischkis, Gerhard Erkel, Karl-Herbert Schäfer

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in physiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. The Gut Mycobiome for Precision Medicine.Journal of fungi (Basel, Switzerland) · 2025
    Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Dominik SchreiberDepartment of Biotechnology, University of Applied Sciences KaiserslauternKaiserslautern, Germany.
Lisa MarxDepartment of Biotechnology, University of Applied Sciences KaiserslauternKaiserslautern, Germany.
Silke FelixDepartment of Biotechnology, Technical University of KaiserslauternKaiserslautern, Germany.
Jasmin ClasohmDepartment of Biotechnology, University of Applied Sciences KaiserslauternKaiserslautern, Germany.
Maximilian WeylandDepartment of Biotechnology, University of Applied Sciences KaiserslauternKaiserslautern, Germany.
Maximilian SchäferDepartment of Biotechnology, University of Applied Sciences KaiserslauternKaiserslautern, Germany.
Markus KlotzDepartment of Biotechnology, University of Applied Sciences KaiserslauternKaiserslautern, Germany.
Rainer LilischkisDepartment of Biotechnology, University of Applied Sciences KaiserslauternKaiserslautern, Germany.
Gerhard ErkelDepartment of Biotechnology, Technical University of KaiserslauternKaiserslautern, Germany.
Karl-Herbert SchäferDepartment of Biotechnology, University of Applied Sciences KaiserslauternKaiserslautern, Germany.
University of Applied Sciences Kaiserslautern · DEUniversity of Kaiserslautern · DEUniversity Medical Centre Mannheim · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inflammatory bowel diseases (IBD), which include Crohn's disease and ulcerative colitis, are chronic inflammatory disorders that can affect the whole gastrointestinal tract or the colonic mucosal layer. Current therapies aiming to suppress the exaggerated immune response in IBD largely rely on compounds with non-satisfying effects or side-effects. Therefore, new therapeutical options are needed. In the present study, we investigated the anti-inflammatory effects of the fungal metabolites, galiellalactone, and dehydrocurvularin in both an

Indexed as

dehydrocurvularindexamethasoneENSgaliellalactoneinflammatory bowel diseaseintestinemesenterial perfusionneuroinflammation

Identifiers

PMID28824460
PMCPMC5545603
OpenAlexW2745180241

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.